Stock ELUT ELUTIA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Elutia Inc.

Equities

ELUT

US05479K1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.25 USD -0.91% Intraday chart for Elutia Inc. -.--% +50.46%
May. 09 Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M MT

Evolution of the average Target Price on Elutia Inc.

Price target over the last 5 years

History of analyst recommendation changes

6ca0bac3a79dd6807533eb98b050b8._Qo-iNjWQ4KTgWQpwamUBZhlIx80wHoeh2LxDz-G3vE.mWEPwYmUAe_j8z1umfHCackVTWtmoiV13gSTRlX8iLuuXmfth7kH6d7DDw~e697f2a1c428651ea5da4a38403c76f8

Analyst Recommendations on Elutia Inc.

Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating MT
Lake Street Initiates Elutia at Buy Rating With $3 Price Target MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed MT
Cantor Fitzgerald Trims Price Target on Aziyo Biologics to $10 From $12, Maintains Overweight Rating MT
Turist Securities Adjusts Aziyo Biologics Price Target to $10 From $8, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on Aziyo Biologics to $10.50 From $9, Maintains Overweight Rating MT
Cowen Adjusts Aziyo Biologics' Price Target to $13 From $15, Keeps Outperform Rating MT
Piper Sandler Adjusts Aziyo Biologics' Price Target to $9 From $11, Reiterates Overweight Rating MT
Piper Sandler Adjusts Aziyo Biologics' Price Target to $11 From $14, Reiterates Overweight Rating MT
AZIYO BIOLOGICS : Piper Sandler Adjusts Aziyo Biologics PT to $14 From $20, Maintains Overweight Rating MT
AZIYO BIOLOGICS : Cantor Fitzgerald Starts Aziyo Biologics at Overweight With $20 Price Target MT
AZIYO BIOLOGICS : Cowen Starts Aziyo Biologics at Outperform With $20 Price Target MT
AZIYO BIOLOGICS : Truist Securities Starts Aziyo Biologics at Buy With $20 Price Target MT
AZIYO BIOLOGICS : Piper Sandler Starts Aziyo Biologics at Overweight With $20 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.25 USD
Average target price
5 USD
Spread / Average Target
+53.85%
High Price Target
5 USD
Spread / Highest target
+53.85%
Low Price Target
5 USD
Spread / Lowest Target
+53.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Elutia Inc.

Cantor Fitzgerald
Lake Street
Truist Securities
Piper Sandler
Cowen

Ratings for Elutia Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ELUT Stock
  4. Consensus Elutia Inc.